Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

PAM50 Breast Cancer Intrinsic Subtypes And Effect Of Gemcitabine In Advanced Breast Cancer Patients

C. Jørgensen, T. Nielsen, Karsten D. Bjerre, S. Liu, Brett Wallden, E. Balslev, Dorte L. Nielsen, B. Ejlertsen
Published 2014 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Abstract Background. In vitro studies suggest basal breast cancers are more sensitive to gemcitabine relative to other intrinsic subtypes. The main objective of this study was to use specimens from a randomized clinical trial to evaluate whether the basal-like subtype identifies patients with advanced breast cancer who benefit from gemcitabine plus docetaxel (GD) compared to single agent docetaxel (D). Material and methods. From patients randomly assigned to GD or D, RNA was isolated from archival formalin-fixed, paraffin-embedded primary breast tumor tissue and used for PAM50 intrinsic subtyping by NanoString nCounter. Statistical analyses were prespecified as a formal prospective-retrospective clinical trial correlative study. Using time to progression (TTP) as primary endpoint, overall survival (OS) and response rate as secondary endpoints, relationships between subtypes and outcome after chemotherapy were analyzed by the Kaplan-Meier method, and Cox proportional hazards regression models. Data analysis was performed independently by the Danish Breast Cancer Cooperative Group (DBCG) statistical core and all statistical tests were two-sided. Results. RNA from 270 patients was evaluable; 84 patients (31%) were classified as luminal A, 97 (36%) luminal B, 43 (16%) basal-like, and 46 (17%) as HER2-enriched. PAM50 intrinsic subtype was a significant independent prognostic factor for both TTP (p = 0.014) and OS (p = 0.0003). Response rate was not different by subtype, and PAM50 was not a predictor of TTP by treatment arm. PAM50 was however a highly significant predictor of OS following GD compared to D (pinteraction = 0.0016). Patients with a basal-like subtype had a significant reduction in OS events [hazard ratio (HR) = 0.29, 95% confidence interval (CI) = 0.15–0.57; pinteraction = 0.0006]. Conclusion. A significantly improved and clinically important prolongation of survival was seen from the addition of gemcitabine to docetaxel in advanced basal-like breast cancer patients.
This paper references
10.1200/JCO.2009.25.9820
Metastatic behavior of breast cancer subtypes.
H. Kennecke (2010)
10.1038/114120c0
The Diseases of the Breast
E. Bell (1924)
10.1200/JCO.2012.46.1558
Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
M. Dowsett (2013)
10.1016/j.critrevonc.2011.01.010
Treatment of metastatic breast cancer: state-of-the-art, subtypes and perspectives.
N. E. El Saghir (2011)
10.1200/JCO.2002.08.125
Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer.
C. V. Van Poznak (2002)
10.1038/nbt1385
Direct multiplexed measurement of gene expression with color-coded probe pairs
G. Geiss (2008)
10.1158/0008-5472.CAN-09-4521
Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin.
Kedar Hastak (2010)
10.1198/016214508000000454
Statistical Significance of Clustering for High-Dimension, Low–Sample Size Data
Yufeng Liu (2008)
10.1200/JCO.2008.17.4839
Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer.
H. Chew (2009)
10.1038/35021093
Molecular portraits of human breast tumours
C. Perou (2000)
10.1158/0008-5472.SABCS12-P2-10-02
Abstract P2-10-02: Clinical validation of the PAM50 risk of recurrence (ROR) score for predicting residual risk of distant-recurrence (DR) after endocrine therapy in postmenopausal women with ER+ early breast cancer (EBC): An ABCSG study
M. Gnant (2012)
10.3816/CBC.2005.N.009
A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane.
S. Modi (2005)
10.1093/jnci/djp335
Use of archived specimens in evaluation of prognostic and predictive biomarkers.
R. Simon (2009)
10.1073/pnas.191367098
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T. Sørlie (2001)
10.2967/jnumed.108.057240
Response to Therapy in Breast Cancer
N. Avril (2009)
10.3816/CBC.2010.n.026
Through a glass darkly: advances in understanding breast cancer biology, 2000-2010.
L. Carey (2010)
10.1007/978-3-319-22843-3_11
Gene Arrays, Prognosis, and Therapeutic Interventions
C. Arslan (2016)
10.1016/J.CCR.2006.10.008
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
R. Neve (2006)
10.1093/JNCI/DJH198
Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer.
G. Konecny (2004)
10.1097/PPO.0b013e318212dee3
Molecular Predictors of Response to Therapy for Breast Cancer
N. Galanina (2011)
10.1200/JCO.2008.18.1370
Supervised risk predictor of breast cancer based on intrinsic subtypes.
J. Parker (2009)
10.1158/1078-0432.CCR-11-2762
Gene Expression, Molecular Class Changes, and Pathway Analysis after Neoadjuvant Systemic Therapy for Breast Cancer
A. González-Angulo (2012)
HER-2/neu gene amplifi cation and response to paclitaxel in patients with metastatic breast cancer
C Van Poznak (2004)
10.1016/J.EJCA.2005.03.032
REporting recommendations for tumour MARKer prognostic studies (REMARK).
L. McShane (2005)
10.1158/1078-0432.CCR-10-1282
A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer
T. Nielsen (2010)
docetaxel; trt, treatment. results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial
D Gd (2007)
10.1097/COC.0b013e3181b4eff9
Is it Possible to Increase pCR in the Neoadjuvant Treatment With a Dose-Dense/Sequential Combination?: Results From a Phase II Trial Combining Epirubicin and Cyclophosphamide Followed by Paclitaxel and Gemcitabine ± Trastuzumab in Stage II and III Breast Cancer Patients
A. Sánchez-muñoz (2010)
Through a glass darkly: Advances in understand
L A Carey
10.1016/S1470-2045(07)70041-4
Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial.
M. Martín (2007)
10.1200/JCO.2007.11.9362
Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment.
K. Albain (2008)
10.1038/ncponc0252
REporting recommendations for tumor MARKer prognostic studies (REMARK)
L. McShane (2005)
Gene arrays, prognosis, and therapeutic
L Carey (2008)
10.1200/JCO.2010.33.9507
Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group.
Dorte L. Nielsen (2011)



This paper is referenced by
10.1093/jnci/djx258
Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results
O. Gluz (2018)
10.2147/BCTT.S71781
BP-C1 in the treatment of patients with stage IV breast cancer: a randomized, double-blind, placebo-controlled multicenter study and an additional open-label treatment phase
S. Larsén (2014)
10.14288/1.0167714
Clinical performance of diagnostic, prognostic and predictive immunohistochemical biomarkers for hormone receptor-negative breast cancer
Jennifer Won (2015)
10.4103/sajc.sajc_117_18
Practical consensus recommendations regarding the management of hormone receptor positive early breast cancer in elderly women
G. Babu (2018)
10.3310/hta23300
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
S. Harnan (2019)
10.2147/CMAR.S213663
The prognosis comparison of different molecular subtypes of breast tumors after radiotherapy and the intrinsic reasons for their distinct radiosensitivity
L. He (2019)
10.1186/s13058-018-1012-0
The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer
M. Jensen (2018)
10.3310/hta20100
OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer.
R. Stein (2016)
10.1186/s12864-016-2903-z
CrossLink: a novel method for cross-condition classification of cancer subtypes
Chifeng Ma (2016)
10.1002/ijc.32488
Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple‐negative early breast cancer: Primary translational analysis of the WSG‐ADAPT‐TN trial
O. Gluz (2019)
CMAR_A_213663 5765..5775
Lin He (2019)
10.1007/s10549-019-05398-3
Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination
S. Swain (2019)
10.1186/s12920-015-0129-6
Development and verification of the PAM50-based Prosigna breast cancer gene signature assay
Brett Wallden (2015)
Universitet TIMP-1 and responsiveness to gemcitabine in advanced breast cancer
C. L. Jørgensen (2014)
10.1080/0284186X.2017.1401735
Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy – results from two independent randomized trials
T. Laurberg (2018)
10.1158/1078-0432.CCR-18-3121
Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas
S. Zhao (2018)
10.1186/1471-2407-14-177
Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens
T. Nielsen (2013)
10.1002/ijc.31969
Basal biomarkers nestin and INPP4B predict gemcitabine benefit in metastatic breast cancer: Samples from the phase III SBG0102 clinical trial
Karama Asleh (2019)
10.1007/978-3-319-46356-8_12
Molecular Classification of Breast Cancer
María N. Vidal (2016)
Breast Cancer: Targets and Therapy Dovepress
()
10.1200/JCO.2015.33.15_SUPPL.E12086
BP-C1 in treatment of patients with stage IV breast cancer: A randomized, double-blind, placebo-controlled multicenter study and additional open-label treatment phase.
S. Larsén (2015)
10.1186/1471-2407-14-360
TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group
C. L. Jørgensen (2014)
10.1089/jamp.2015.1286
Development of Optimized, Inhalable, Gemcitabine-Loaded Gelatin Nanocarriers for Lung Cancer.
Susanne R. Youngren-Ortiz (2017)
10.1080/0284186X.2017.1360514
Intrinsic subtype characterization of local recurrences and new contralateral primary tumors in patients with low risk breast cancer. Influence of age and primary surgery
T. Laurberg (2017)
10.1002/bjs.9562
Lessons learned from the intrinsic subtypes of breast cancer in the quest for precision therapy
J. H. Norum (2014)
10.1007/s10549-014-3259-1
Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial
S. Liu (2014)
Semantic Scholar Logo Some data provided by SemanticScholar